Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $10.1667.

A number of analysts have recently commented on the company. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. HC Wainwright began coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They set a “buy” rating and a $10.00 target price for the company. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th.

Marker Therapeutics Stock Performance

NASDAQ:MRKR opened at $1.48 on Friday. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The firm has a market cap of $24.67 million, a price-to-earnings ratio of -1.20 and a beta of 1.44. The firm’s fifty day moving average is $1.66 and its two-hundred day moving average is $1.27.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the 2nd quarter valued at about $33,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics in the third quarter valued at approximately $33,000. Virtu Financial LLC acquired a new position in shares of Marker Therapeutics during the 3rd quarter worth approximately $25,000. Boyer Financial Services Inc. purchased a new position in shares of Marker Therapeutics during the 4th quarter valued at approximately $57,000. Finally, Geode Capital Management LLC lifted its position in shares of Marker Therapeutics by 35.3% during the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.